Literature DB >> 16728461

Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

A W R van Kuijk1, P Reinders-Blankert, T J M Smeets, B A C Dijkmans, P P Tak.   

Abstract

BACKGROUND: The synovial tissue is a primary target of many inflammatory arthropathies, including psoriatic arthritis (PsA). Identification of proinflammatory molecules in the synovium may help to identify potentially therapeutic targets.
OBJECTIVE: To investigate extensively the features of cell infiltration and expression of mediators of inflammation and joint destruction in the synovium of patients with PsA compared with patients with rheumatoid arthritis matched for disease duration and use of drugs.
METHODS: Multiple synovial tissue biopsy specimens were obtained by arthroscopy from an inflamed joint in 19 patients with PsA (eight oligoarthritis, 11 polyarthritis) and 24 patients with rheumatoid arthritis. Biopsy specimens were analysed by immunohistochemistry to detect T cells, plasma cells, fibroblast-like synoviocytes, macrophages, proinflammatory cytokines, matrix metalloproteinases and tissue inhibitor metalloproteinase-1, adhesion molecules and vascular markers. Stained sections were evaluated by digital image analysis.
RESULTS: The synovial infiltrate of patients with PsA and rheumatoid arthritis was comparable with regard to numbers of fibroblast-like synoviocytes and macrophages. T cell numbers were considerably lower in the synovium of patients with PsA. The number of plasma cells also tended to be lower in PsA. The expression of tumour necrosis factor alpha (TNFalpha), interleukin (IL) 1beta, IL6 and IL18 was as high in PsA as in rheumatoid arthritis. The expression of matrix metalloproteinases, adhesion molecules and vascular markers was comparable for PsA and rheumatoid arthritis.
CONCLUSION: These data show increased proinflammatory cytokine expression in PsA synovium, comparable to results obtained for rheumatoid arthritis, and support the notion that, in addition to TNFalpha blockade, there may be a rationale for treatments directed at IL1beta, IL6 and IL18.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728461      PMCID: PMC1798447          DOI: 10.1136/ard.2005.050963

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  54 in total

1.  Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis.

Authors:  P P Youssef; D R Haynes; S Triantafillou; A Parker; J R Gamble; P J Roberts-Thomson; M J Ahern; M D Smith
Journal:  Arthritis Rheum       Date:  1997-08

2.  Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis.

Authors:  D Creamer; M H Allen; A Sousa; R Poston; J N Barker
Journal:  Br J Dermatol       Date:  1997-06       Impact factor: 9.302

3.  Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression.

Authors:  P P Youssef; S Triantafillou; A Parker; M Coleman; P J Roberts-Thomson; M J Ahern; M D Smith
Journal:  Arthritis Rheum       Date:  1996-12

4.  Patterns of cytokine production in psoriatic synovium.

Authors:  C Ritchlin; S A Haas-Smith; D Hicks; J Cappuccio; C K Osterland; R J Looney
Journal:  J Rheumatol       Date:  1998-08       Impact factor: 4.666

5.  Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.

Authors:  P Ettehadi; M W Greaves; D Wallach; D Aderka; R D Camp
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

6.  Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.

Authors:  P P Tak; P A van der Lubbe; A Cauli; M R Daha; T J Smeets; P M Kluin; A E Meinders; G Yanni; G S Panayi; F C Breedveld
Journal:  Arthritis Rheum       Date:  1995-10

7.  Expression of adhesion molecules in early rheumatoid synovial tissue.

Authors:  P P Tak; E W Thurkow; M R Daha; P M Kluin; T J Smeets; A E Meinders; F C Breedveld
Journal:  Clin Immunol Immunopathol       Date:  1995-12

8.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

9.  Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin.

Authors:  O J de Boer; I M Wakelkamp; S T Pals; N Claessen; J D Bos; P K Das
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.

Authors:  M Detmar; L F Brown; K P Claffey; K T Yeo; O Kocher; R W Jackman; B Berse; H F Dvorak
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  65 in total

1.  [Psoriasis arthritis. An interdisciplinary challenge].

Authors:  M A Radtke; K Reich; F Beikert; M Augustin
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

2.  Transcriptional network profile on synovial fluid T cells in psoriatic arthritis.

Authors:  Ugo Fiocco; Veronica Martini; Benedetta Accordi; Francesco Caso; Luisa Costa; Francesca Oliviero; Anna Scanu; Monica Facco; Daniele Boso; Mariele Gatto; Mara Felicetti; Paola Frallonardo; Roberta Ramonda; Lucia Piva; Renato Zambello; Carlo Agostini; Raffaele Scarpa; Giuseppe Basso; Gianpietro Semenzato; Jean-Michel Dayer; Leonardo Punzi; Andrea Doria
Journal:  Clin Rheumatol       Date:  2015-07-09       Impact factor: 2.980

Review 3.  Drivers of Inflammation in Psoriatic Arthritis: the Old and the New.

Authors:  Charlotte O'Brien-Gore; Elizabeth H Gray; Lucy E Durham; Leonie S Taams; Bruce W Kirkham
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 4.  The History of Psoriatic Arthritis (PsA): From Moll and Wright to Pathway-Specific Therapy.

Authors:  Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2018-08-09       Impact factor: 4.592

Review 5.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

6.  Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?

Authors:  Oliver FitzGerald
Journal:  Nat Rev Rheumatol       Date:  2016-05-24       Impact factor: 20.543

Review 7.  MRI in psoriatic arthritis: insights into pathogenesis and treatment response.

Authors:  Fiona M McQueen; Nicola Dalbeth; Anthony Doyle
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

8.  Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis.

Authors:  Jeffrey H Ruth; Christy C Park; M Asif Amin; Charles Lesch; Hubert Marotte; Shiva Shahrara; Alisa E Koch
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

Review 9.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

10.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.

Authors:  A W R van Kuijk; D M Gerlag; K Vos; G Wolbink; M de Groot; M A de Rie; A H Zwinderman; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-07-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.